M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Lenalidomide and its role in the management of multiple myeloma
Patrizia Falco,Federica Cavallo,Alessandra Larocca,Anna Marina Liberati,Pellegrino Musto,Mario Boccadoro,Antonio Palumbo +6 more
TL;DR: Lenalidomide is an oral analogue of thalidomides that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity.
Journal ArticleDOI
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.
Chiara Lobetti-Bodoni,Barbara Mantoan,Luigia Monitillo,Elisa Genuardi,Daniela Drandi,Daniela Barbero,Elisa Bernocco,Mario Boccadoro,Marco Ladetto +8 more
TL;DR: This review focuses on critical take-home messages for clinicians working in the field of minimal residual disease evaluation in FL and future perspectives of MRD detection and more generally outcome prediction in FL.
Journal ArticleDOI
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients.
Antonio Palumbo,Sara Bringhen,Maria Teresa Petrucci,Antonietta Falcone,Anna Marina Liberati,Vito Michele Lauta,Mariella Grasso,Marco Montanaro,Francesco Pisani,Tommaso Caravita,Clotilde Cangialosi,Patrizia Pregno,Andrea Nozza,Elisabetta Calabrese,Federica Cavallo,Paola Omedè,Pellegrino Musto,Robin Foà,Mario Boccadoro +18 more
TL;DR: MEL200 resulted in a significantly higher near complete response rate than MEL100, but partial response was 80% versus 71%, respectively (p=0.011), and gastrointestinal toxicities were similar in both groups.
Journal ArticleDOI
Human Myeloma: Kinetics of the Remission Phase
TL;DR: It is shown that the residual myeloma cell labelling index during remission is usually lower than that observable on diagnosis, which conflicts with the current opinion on minimal tumor mass kinetics.
Journal ArticleDOI
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
Antonio Palumbo,Alessandra Larocca,Vittorio Montefusco,Davide Rossi,Angelo Michele Carella,Roberto Mina,Claudia Crippa,Mariella Sciacca,Monica Galli,Delia Rota Scalabrini,Magda Marcatti,Tommasina Guglielmelli,Nicola Giuliani,Giacinto La Verde,Ileana Baldi,Vittorio Emanuele Muccio,Mario Boccadoro,Paolo Corradini +17 more
TL;DR: PCP induced high response rates and prolonged PFS after prior exposure to lenalidomide and bortezomib, without adding significant toxicity, and could be considered a valuable salvage option for pre-treated MM patients.